Introduction
Ionis (IONS) is a mid-cap ($9.3B) pharmaceuticals and a leader in RNA-targeted drug discovery and development. Its diverse pipeline comprises drug targets for neurological, cardiometabolic, renal, rare/orphan and oncological diseases. In line with its business model, IONS has multiple royalty revenue streams due to the significant number of collaborative/license agreements with small, mid and large-cap biopharmas.
This article focuses on the investigative drug candidate, IONIS-GHR-LRx, second-generation ligand-conjugated antisense (LICA.) investigative drug candidate in two Phase 2 studies for Acromegaly.
Acromegaly is a rare hormonal disease caused by over-secretion of growth hormone